Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · Real-Time Price · USD
0.290
+0.007 (2.55%)
At close: Feb 21, 2025, 4:00 PM
0.285
-0.005 (-1.72%)
After-hours: Feb 21, 2025, 7:57 PM EST
Oragenics Revenue
In the year 2023, Oragenics had annual revenue of $37.65K, down -71.37%.
Revenue (ttm)
$37.65K
Revenue Growth
-71.37%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
3.92M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
OGEN News
- 12 days ago - Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment - GlobeNewsWire
- 18 days ago - Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025 - GlobeNewsWire
- 4 weeks ago - Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO - GlobeNewsWire
- 2 months ago - Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference - GlobeNewsWire
- 4 months ago - Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit - GlobeNewsWire
- 4 months ago - Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation - GlobeNewsWire
- 4 months ago - Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002 - GlobeNewsWire
- 6 months ago - Oragenics, Inc. Announces Closing of Public Offering - GlobeNewsWire